Navigation Links
Further Studies on AIDS Prevention Gels Stopped

Researchers have discontinued further studies on anti-AIDS vaginal gel in Africa and India, following results of recent trials, which indicated// that it could enhance the risk of HIV infection, instead of reducing it.

The gel in question, called Ushercell, contains a cotton-based compound called cellulose sulfate. This gel is developed by Polydex Pharmaceuticals, a company in Toronto.

More than 50% of AIDS infections in Africa concern women and girls. Researchers have been contemplating the employment of other protective measures which could be used by women, even without the knowledge of their partners. Scientists thought this would help in the scenario of many men refusing to use any protection during sex.

A study with 1,500 women in South Africa, Benin, Uganda, and India had to be halted during this week after a supervising board observed an increase in HIV infections among women using the gel, in contrast to women who were given an inactive medication.

"I cannot think of any biological basis for these findings, and I hope that further analysis of all of the data may shed further light on this important question," said USAID's research chief, Jeff Spieler.

"We did not find any evidence of greater risk of HIV infection," said a statement from Dr. Vera Halpern, who had spearheaded the Nigeria study. "But we also found no evidence that the product was effective."

Almost eleven trials had been conducted in The United States to evaluate the effectiveness of this gel, which had found the product to be safe and effective.
'"/>




Page: 1

Related medicine news :

1. Further support for use of statins in Alzheimer’s disease
2. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
3. Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered
4. NHS Recommends Further Cost Cutting Measures
5. Medha Patkars Condition Deteriorates Further
6. Oxford Radcliffe Hospitals Warns Of Further Job Losses
7. Further Studies Needed To Completely Understand About Ventricular Fibrillation
8. Further improvements envisaged at Carstairs
9. UCLA Find Yields Further Insight into Causes of Parkinson’s Diseas
10. Salt Consumption Needs To Drop Further
11. Studies On Hearing Loss Discovers New Causes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina ... of New York was founded by James M. Maisel, MD and has been providing tertiary ... has always followed a legacy of surpassing expectations amongst her peers. Growing up in ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Surgical Facial Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The ... The Aesthetic & Anti-aging Medicine European Congress (AMEC) brings together the industry’s ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 03, 2016 , ... Penrose Senior Care Auditors® was announced ... evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and Banquet ... for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, commitment ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges on regular brushing of ... optimal results. This important necessity inspired an inventor from Las Vegas, Nev., to design ... that people break or avoid bad techniques of brushing the teeth in order to ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... Taiwan , Dec. 5, 2016 ... non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... profile of ropeginterferon alfa-2b versus HU AOP ... follow-up trial CONTINUATION-PV to obtain European marketing authorization in the ... data to the FDA as it seeks approval for commercialization ...
(Date:12/4/2016)... --  Pairnomix, LLC, a genetic research company and member ... White House, today announced that findings from its first case ... therapies for a patient with epileptic encephalopathy caused by a ... the 70 th Annual Meeting of the American ... December 2-6, 2016.  Pairnomix, unique process involves creating ...
Breaking Medicine Technology: